David Mott is on these Sector & Stage Rankings

David Mott's Investments On Record (14)

Company	StageDateRound Size	Total Raised
Sagimet Biosciences	Series EAug 2019$7M	$113.6M
Co-investors: Robert Garland (New Enterprise Associates), Beth Seidenberg (Westlake Village BioPartners)
Nightstar Therapeutics	Series CJun 2017$45M Series BNov 2015$35M	$80M
Ardelyx	Post-IPO EquityJul 2016$110M Post-IPO EquityJun 2015$77.8M Series BAug 2011$30M	$217.8M
Clementia Pharmaceuticals	Venture RoundJun 2015$60M	$60M
Adaptimmune	Series ASep 2014$104M	$104M
Co-investors: Ali Behbahani (New Enterprise Associates)
Cydan	Venture RoundOct 2013$10M Venture RoundApr 2013$16M	$26M
Edimer Pharmaceuticals	Series BJul 2013$18M	$18M
Prosensa	Venture RoundJan 2012€23M	€23M
Omthera Pharmaceuticals	Series BMar 2011$33.9M	$33.9M
Epizyme	Series BDec 2009$8M	$40M
Co-investors: Kazumi Shiosaki (MPM Capital), Beth Seidenberg (Westlake Village BioPartners)